These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 30132080)

  • 1. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
    Ip A; Della Pia A; Goy AH
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):491-505. PubMed ID: 38493059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.
    Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S
    Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.
    Gallucci Figorelle L; Galvão PT; de Lima FMR; Marimon P; Pentagna N; Milito C; Schaffel R; Carneiro K
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):433-445. PubMed ID: 38641485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
    Li S; Tang G; Jain P; Lin P; Xu J; Miranda RN; Cheng J; Yin CC; You MJ; Wang ML; Medeiros LJ
    Mod Pathol; 2024 Feb; 37(2):100405. PubMed ID: 38104893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
    Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
    Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.
    Zeng W; Fu K; Quintanilla-Fend L; Lim M; Ondrejka S; Hsi ED
    Am J Surg Pathol; 2012 Feb; 36(2):214-9. PubMed ID: 22251940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling and management of mantle cell lymphoma.
    Ruan J
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.
    Kurita D; Takeuchi K; Kobayashi S; Hojo A; Uchino Y; Sakagami M; Ohtake S; Takahashi H; Miura K; Iriyama N; Sugitani M; Miyoshi H; Hatta Y; Ohshima K; Takei M
    Virchows Arch; 2016 Oct; 469(4):471-6. PubMed ID: 27457074
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
    Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
    Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
    Isaac KM; Portell CA; Williams ME
    Curr Oncol Rep; 2021 Jul; 23(9):102. PubMed ID: 34269910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
    He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
    Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoldering mantle cell lymphoma.
    Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
    J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
    Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
    Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.